Date: 2013-09-03
Type of information: Private placement
Company: Leukocare (Germany)
Investors:
Amount: € 3.4 million
Funding type: private placement
Planned used: This fundraising will be used to accelerate the growth of Leukocare\'s business and to develop markets of its technology portfolio. Leukocare licenses proprietary technologies for stabilization and protection of proteins and other biologics against chemical and physical stress to partners in the fields of biopharmaceutical, medical device, and diagnostic industries. The company also offers know-how and experience in collaborative product development to support incorporation of its Stabilizing and Protecting Solutions (SPS) into new products. In the next 2 years, Leukocare expects industrial partners in the fields of vaccines, combination products and biopharmaceuticals to start commercializing products employing our technologies.
Others: * On September 3, 2013, Leukocare, a german provider of stabilizing and protecting formulation technologies for biologics, has announced the successful completion of its capital increase of € 3.4 million. New ordinary shares were issued to existing shareholders and new investors in exchange for a combination of new equity capital and the conversion of an outstanding € 1.0 million corporate bond.
Therapeutic area:
